Anti-SLC6A14 (extracellular)

Antibodies

Sodium and chloride-dependent neutral and basic amino acid transporter B(0+), Amino acid transporter ATB0+, Solute carrier family 6 member 14

Shipped at room temperature. Product as supplied can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C

Lyophilized powder. Reconstituted antibody contains phosphate buffered saline (PBS), pH 7.4

Sodium and chloride-dependent neutral and basic amino acid transporter B(0+), Amino acid transporter ATB0+, Solute carrier family 6 member 14 - A Rabbit Polyclonal Antibody to SLC6A14 Transporter

Mouse - 12/14 amino acid residues identical; rat - 11/14 amino acid residues identical

Confirmed by amino acid analysis and mass spectrometry

0.8 mg/ml

2nd extracellular loop

Human

41116161

SLC614A is an amino acid transporter which is a member of the Solute carrier (SLC) 6 transporter family. Currently, the SLC6 family is comprised of >300 prokaryotic and eukaryotic proteins, of which 21 have been identified in humans. SLC6 members have 12 membrane spanning domains (TM) with intracellular N- and C- termini1.SLC614A transports all amino acids (except glutamate and aspartate) into the cell. It has a uni-directional function and it is energized by three different driving forces: a Na+ gradient, a Cl- gradient and the membrane potential. These specific characteristics makes it important in the development of cancerous tumors2. During carcinogenesis, the developing tumor utilizes more resources than healthy tissue and, therefore, there is an over-production of transporters for glucose and amino acids. SLC614A is uniquely suited to the biological needs of tumor cells: Theoretically, this transporter has the ability to concentrate its substrates inside the cell ~1000-fold compared to the extracellular medium, which complies with the increasing demand of the tumor cell for amino acid supply2. Indeed, SLC614A has been shown to be up regulated in multiple cancer types such as, cervical cancer3, breast cancer4, and pancreatic cancer5, as well as the development of Cystic fibrosis6. Hence, the therapeutic potential in affecting the activity of this transporter is clinically significant.